Developmental Therapeutics Recent Publications
2024
- Practical utilization of nonlinear spatial encoding: Fast field mapping and FRONSAC-wave.Zhang HZ, Constable RT, Galiana G. Magn Reson Med. 2024 Sep; 2024 Apr 23. PMID: 38651264.
- Intramolecular Oxyalkylation of Unactivated Alkenes.Xu Z, Airan Y, Tomanik M, Yang AT, Bhak N, Herzon SB. Tetrahedron. 2024 Jul 17; 2024 May 31. PMID: 38911481.
- Assessing readiness to use electronic health record data for outcome ascertainment in clinical trials - A case study.Esserman D, Greene EJ, Latham NK, Kane M, Lu C, Peduzzi PN, Gill TM, Ganz DA. Contemp Clin Trials. 2024 Jul; 2024 May 11. PMID: 38740298.
- Sarcomatoid and Rhabdoid Renal Cell Carcinoma: Clinical, Pathologic, and Molecular Genetic Features.Adeniran AJ, Shuch B, Humphrey PA. Am J Surg Pathol. 2024 Jul 1; 2024 May 13. PMID: 38736105.
- Constrained alternating minimization for parameter mapping (CAMP).Elsaid NMH, Dispenza NL, Hu C, Peters DC, Constable RT, Tagare HD, Galiana G. Magn Reson Imaging. 2024 Jul; 2024 Apr 23. PMID: 38657714.
- Validation of a Rule-Based ICD-10-CM Algorithm to Detect Fall Injuries in Medicare Data.Ganz DA, Esserman D, Latham NK, Kane M, Min LC, Gill TM, Reuben DB, Peduzzi P, Greene EJ. J Gerontol A Biol Sci Med Sci. 2024 Jul 1. PMID: 38566617.
- Disparities in race, ethnicity, sex, and age inclusion in pancreatic cancer screening studies: a systematic review and meta-analysis.Silva-Santisteban A, Hernandez Woodbine MJ, Noriega MA, Rabinowitz LG, Grimshaw A, Farrell JJ, Chhoda A, Sawhney MS. Gastrointest Endosc. 2024 Jul; 2024 Mar 1. PMID: 38432492.
- Intensive Induction Chemotherapy versus Hypomethylating Agents in Combination with Venetoclax in NPM1-mutant AML.Bewersdorf JP, Shimony S, Shallis RM, Liu Y, Berton G, Schaefer EJ, Zeidan AM, Goldberg AD, Stein EM, Marcucci G, Bystrom R, Lindsley RC, Chen EC, Ramos Perez JM, Stein AS, Pullarkat VA, Aldoss I, DeAngelo DJ, Neuberg DS, Stone RM, Garciaz S, Ball BJ, Stahl M. Blood Adv. 2024 Jun 28; 2024 Jun 28. PMID: 38941537.
- Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity.Locke FL, Siddiqi T, Jacobson CA, Ghobadi A, Ahmed S, Miklos DB, Perales MA, Munoz J, Fingrut WB, Pennisi M, Gauthier J, Shadman M, Gowda L, Mirza AS, Abid MB, Hong S, Majhail NS, Kharfan-Dabaja MA, Khurana A, Badar T, Lin Y, Bennani NN, Herr MM, Hu ZH, Wang HL, Baer A, Baro E, Miao H, Spooner C, Xu H, Pasquini MC. Blood. 2024 Jun 27. PMID: 38635762.
- A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170).Maldonado E, Rathmell WK, Shapiro GI, Takebe N, Rodon J, Mahalingam D, Trikalinos NA, Kaleblasty AR, Parikh M, Boerner SA, Balido C, Krings G, Burns TF, Bergsland EK, Munster PN, Ashworth A, LoRusso P, Aggarwal RR. Cancer Res Commun. 2024 Jun 26; 2024 Jun 26. PMID: 38920407.
- Fe/Thiol Cooperative Hydrogen Atom Transfer Olefin Hydrogenation: Mechanistic Insights That Inform Enantioselective Catalysis.Buzsaki SR, Mason SM, Kattamuri PV, Serviano JMI, Rodriguez DN, Wilson CV, Hood DM, Ellefsen JD, Lu YC, Kan J, West JG, Miller SJ, Holland PL. J Am Chem Soc. 2024 Jun 26; 2024 Jun 14. PMID: 38875703.
- Neutrophils insert elastase into hepatocytes to regulate calcium signaling in alcohol-associated hepatitis.Ogino N, Leite MF, Guerra MT, Kruglov E, Asashima H, Hafler DA, Ito T, Pereira JP, Peiffer BJ, Sun Z, Ehrlich BE, Nathanson MH. J Clin Invest. 2024 Jun 25; 2024 Jun 25. PMID: 38916955.
- The Xenorhabdus nematophila LrhA transcriptional regulator modulates production of γ-keto-N-acyl amides with inhibitory activity against mutualistic host nematode egg hatching.Lam YC, Hamchand R, Mucci NC, Kauffman SJ, Dudkina N, Reagle EV, Casanova-Torres ÁM, DeCuyper J, Chen H, Song D, Thomas MG, Palm NW, Goodrich-Blair H, Crawford JM. Appl Environ Microbiol. 2024 Jun 25; 2024 Jun 25. PMID: 38916293.
- Author Correction: Inhibition of lysine acetyltransferase KAT6 in ER(+)HER2(-) metastatic breast cancer: a phase 1 trial.Mukohara T, Park YH, Sommerhalder D, Yonemori K, Hamilton E, Kim SB, Kim JH, Iwata H, Yamashita T, Layman RM, Mita M, Clay T, Chae YS, Oakman C, Yan F, Kim GM, Im SA, Lindeman GJ, Rugo HS, Liyanage M, Saul M, Le Corre C, Skoura A, Liu L, Li M, LoRusso PM. Nat Med. 2024 Jun 24; 2024 Jun 24. PMID: 38914862.
- Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2.Mutlu L, McNamara B, Bellone S, Manavella DD, Demirkiran C, Greenman M, Verzosa MSZ, Buza N, Hui P, Hartwich TMP, Harold J, Yang-Hartwich Y, Zipponi M, Altwerger G, Ratner E, Huang GS, Clark M, Andikyan V, Azodi M, Schwartz PE, Santin AD. Clin Exp Metastasis. 2024 Jun 22; 2024 Jun 22. PMID: 38909139.
- Topography of mutational signatures in non-small cell lung cancer: emerging concepts, clinical applications, and limitations.Jayakrishnan R, Kwiatkowski DJ, Rose MG, Nassar AH. Oncologist. 2024 Jun 22; 2024 Jun 22. PMID: 38907669.
- Procoagulant phenotype of virus-infected pericytes is associated with portal thrombosis and intrapulmonary vascular dilations in fatal COVID-19.Cadamuro M, Lasagni A, Radu CM, Calistri A, Pilan M, Valle C, Bonaffini PA, Vitiello A, Toffanin S, Venturin C, Friòn-Herrera Y, Sironi S, Alessio MG, Previtali G, Seghezzi M, Gianatti A, Strazzabosco M, Strain AJ, Campello E, Spiezia L, Palù G, Frigo AC, Tosoni A, Nebuloni M, Parolin C, Sonzogni A, Simioni P, Fabris L. J Hepatol. 2024 Jun 20; 2024 Jun 20. PMID: 38908437.
- Outcomes Following Implementation of an Electronic Model for Perioperative Hematologic Consultation.Su DG, Rehman S, Wang K, Deng Y, Rose MG, Dosani T, Kunstman JW. J Surg Res. 2024 Jun 20; 2024 Jun 20. PMID: 38905768.
- Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer: A Nonrandomized Controlled Trial.Cecchini M, Salem RR, Robert M, Czerniak S, Blaha O, Zelterman D, Rajaei M, Townsend JP, Cai G, Chowdhury S, Yugawa D, Tseng R, Mejia Arbelaez C, Jiao J, Shroyer K, Thumar J, Kortmansky J, Zaheer W, Fischbach N, Persico J, Stein S, Khan SA, Cha C, Billingsley KG, Kunstman JW, Johung KL, Wiess C, Muzumdar MD, Spickard E, Aushev VN, Laliotis G, Jurdi A, Liu MC, Escobar-Hoyos L, Lacy J. JAMA Oncol. 2024 Jun 20; 2024 Jun 20. PMID: 38900452.
- Risk Factors and Contemporary Management Options for Pain and Discomfort Experienced During a Prostate Biopsy.Diaz GM, Webb LT, Rabil MJ, Lokeshwar SD, Choksi AU, Leapman MS, Sprenkle PC. Curr Urol Rep. 2024 Jun 19; 2024 Jun 19. PMID: 38896314.
- Latrophilin-2 mediates fluid shear stress mechanotransduction at endothelial junctions.Tanaka K, Chen M, Prendergast A, Zhuang Z, Nasiri A, Joshi D, Hintzen J, Chung M, Kumar A, Mani A, Koleske A, Crawford J, Nicoli S, Schwartz MA. EMBO J. 2024 Jun 17; 2024 Jun 17. PMID: 38886581.
- Integrated genetic, epigenetic, and immune landscape of TP53 mutant AML and higher risk MDS treated with azacitidine.Zeidan AM, Bewersdorf JP, Hasle V, Shallis RM, Thompson E, de Menezes DL, Rose S, Boss I, Halene S, Haferlach T, Fox BA. Ther Adv Hematol. 2024; 2024 Jun 15. PMID: 38883163.
- Targetable ERBB2/HER2 Mutations in Gynecologic Malignancies: Clinicopathological, Immunohistochemical, and Molecular Correlations.Manrai PA, McHenry A, Sun T, Santin AD, Ratner E, Lin DI, Elvin JA, Hui P, Buza N. Int J Gynecol Pathol. 2024 Jun 10; 2024 Jun 10. PMID: 38914011.
- Bifunctional Molecules That Induce Both Targeted Degradation and Transcytosis of Extracellular Proteins in Brain Cells.Howell RA, Wang S, Khambete M, McDonald DM, Spiegel DA. J Am Chem Soc. 2024 Jun 10; 2024 Jun 10. PMID: 38855935.
- Cost-effectiveness analysis: The missing factor in the management of HCC.Njei B, Yi I, Strazzabosco M. Clin Liver Dis (Hoboken). 2024 Jan-Jun; 2024 Jun 7. PMID: 38860130.
- Copper-Catalyzed Three-Component Synthesis of Highly Substituted Morpholines.Chu D, Zoll AJ, Ellman JA. Org Lett. 2024 Jun 7; 2024 May 29. PMID: 38810982.
- Spatially informed gene signatures for response to immunotherapy in melanoma.Aung TN, Warrell J, Martinez-Morilla S, Gavrielatou N, Vathiotis I, Yaghoobi V, Kluger HM, Gerstein M, Rimm DL. Clin Cancer Res. 2024 Jun 5; 2024 Jun 5. PMID: 38837895.
- Development of a Longitudinal Prostate Cancer Transcriptomic and Clinical Data Linkage.Leapman MS, Ho J, Liu Y, Filson CP, Zhao X, Hakansson A, Proudfoot JA, Davicioni E, Martin DT, An Y, Seibert TM, Lin DW, Spratt DE, Cooperberg MR, Ross AE, Sprenkle PC. JAMA Netw Open. 2024 Jun 3; 2024 Jun 3. PMID: 38874922.
- A small-molecule allele-selective transcriptional inhibitor of the MIF immune susceptibility locus.Li J, Leng L, Pantouris G, Manjula R, Piecychna M, Abriola L, Hu B, Lolis E, Armstrong ME, Donnelly SC, Bucala R. J Biol Chem. 2024 Jun 3; 2024 Jun 3. PMID: 38838773.
- A process to reanalyze clinical DNA sequencing data for biomarker matching in the Lung-MAP Master Protocol.Neal JW, Minichiello K, Brennick R, Huang RSP, Hiemenz MC, Amler C, Patel J, Herbst R, Reckamp KL, Borghaei H, Highleyman L, Redman MW, Pasquina LW, Kozono DE. Oncologist. 2024 Jun 3. PMID: 38597608.
- Big Decisions on Small Cell Lung Cancer: A Focus on Clinical Care Updates and Patient Perspectives.Wang X, Chiang AC. Am Soc Clin Oncol Educ Book. 2024 Jun. PMID: 38830134.
- Unlocking the Potential: Biomarkers of Response to Antibody-Drug Conjugates.Ascione L, Guidi L, Prakash A, Trapani D, LoRusso P, Lou E, Curigliano G. Am Soc Clin Oncol Educ Book. 2024 Jun 1. PMID: 38828973.
- Inhibition of lysine acetyltransferase KAT6 in ER(+)HER2(-) metastatic breast cancer: a phase 1 trial.Mukohara T, Park YH, Sommerhalder D, Yonemori K, Hamilton E, Kim SB, Kim JH, Iwata H, Yamashita T, Layman RM, Mita M, Clay T, Chae YS, Oakman C, Yan F, Kim GM, Im SA, Lindeman GJ, Rugo HS, Liyanage M, Saul M, Le Corre C, Skoura A, Liu L, Li M, LoRusso PM. Nat Med. 2024 Jun 1; 2024 Jun 1. PMID: 38824244.
- Navigating the Complexities of Brain Metastases Management.Amouzegar A, Haig S, Kahn AM, Tawbi HA, Jones JA, Goldberg SB. Am Soc Clin Oncol Educ Book. 2024 Jun. PMID: 38781565.
- Pragmaticism in Cancer Clinical Trials.Sankar K, Redman MW, Dragnev KH, Henick BS, Iams WT, Blanke CD, Herbst RS, Gray JE, Reckamp KL. Am Soc Clin Oncol Educ Book. 2024 Jun. PMID: 38771997.
- Correction to: Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities.Kewan T, Stahl M, Bewersdorf JP, Zeidan AM. Curr Hematol Malig Rep. 2024 Jun. PMID: 38761360.
- Safety and Efficacy of Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma and Impaired Liver Function: A Systematic Review and Meta-Analysis.Pasta A, Calabrese F, Jaffe A, Labanca S, Marenco S, Pieri G, Plaz Torres MC, Strazzabosco M, Giannini EG. Liver Cancer. 2024 Jun; 2023 Oct 14. PMID: 38756146.
- Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities.Kewan T, Stahl M, Bewersdorf JP, Zeidan AM. Curr Hematol Malig Rep. 2024 Jun; 2024 Apr 18. PMID: 38632155.
- Clinical activity, pharmacokinetics, and pharmacodynamics of oral hypomethylating agents for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: A multidisciplinary review.Haumschild R, Kennerly-Shah J, Barbarotta L, Zeidan AM. J Oncol Pharm Pract. 2024 Jun; 2024 Mar 21. PMID: 38509812.
- Ligand-gated ion channels as potential biomarkers for ADT-mediated cognitive decline in prostate cancer patients.Verma S, Singh V, Nagampalli V, Ponsky LE, Li CR, Chao H, Gupta S. Mol Carcinog. 2024 Jun; 2024 Mar 14. PMID: 38482990.
- Providing 0.1 Full-Time Equivalent (FTE) Support to Fellowship Core Faculty Improves Faculty Involvement in Fellowship Education and Recruitment.Butt A, Christian J, Kress A, Lu BY, Hurwitz ME, Goldberg SB, Podoltsev NA, Gilkes L, Lee AI. J Cancer Educ. 2024 Jun; 2024 Mar 2. PMID: 38430454.
- Multiplexable and Scalable Aqueous Synthesis Platform for Oleate-Based, Bilayer-Coated Gold Nanoparticles.Backhaus A, Albrecht J, Alzhanova G, Long A, Arnold W, Lee J, Tse HY, Su TT, Cruz-Gomez S, Lee SSS, Menges F, Parent LR, Ratjen L, Burtness B, Fortner JD, Zimmerman JB. Small. 2024 Jun; 2024 Feb 20. PMID: 38377304.
- Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial.Roussos Torres ET, Ho WJ, Danilova L, Tandurella JA, Leatherman J, Rafie C, Wang C, Brufsky A, LoRusso P, Chung V, Yuan Y, Downs M, O'Connor A, Shin SM, Hernandez A, Engle EL, Piekarz R, Streicher H, Talebi Z, Rudek MA, Zhu Q, Anders RA, Cimino-Mathews A, Fertig EJ, Jaffee EM, Stearns V, Connolly RM. Nat Cancer. 2024 Jun; 2024 Feb 14. PMID: 38355777.
- Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study.Nassar AH, Kim SY, Aredo JV, Feng J, Shepherd F, Xu C, Kaldas D, Gray JE, Dilling TJ, Neal JW, Wakelee HA, Liu Y, Lin SH, Abuali T, Amini A, Nie Y, Patil T, Lobachov A, Bar J, Fitzgerald B, Fujiwara Y, Marron TU, Thummalapalli R, Yu H, Owen DH, Sharp J, Farid S, Rocha P, Arriola E, D'Aiello A, Cheng H, Whitaker R, Parikh K, Ashara Y, Chen L, Sankar K, Harris JP, Nagasaka M, Ayanambakkam A, Velazquez AI, Ragavan M, Lin JJ, Piotrowska Z, Wilgucki M, Reuss J, Luders H, Grohe C, Baena Espinar J, Feiner E, Punekar SR, Gupta S, Leal T, Kwiatkowski DJ, Mak RH, Adib E, Naqash AR, Goldberg SB. J Thorac Oncol. 2024 Jun; 2024 Jan 24. PMID: 38278303.
- Mechanism of Action of KL-50, a Candidate Imidazotetrazine for the Treatment of Drug-Resistant Brain Cancers.Huseman ED, Lo A, Fedorova O, Elia JL, Gueble SE, Lin K, Sundaram RK, Oh J, Liu J, Menges F, Rees MG, Ronan MM, Roth JA, Batista VS, Crawford JM, Pyle AM, Bindra RS, Herzon SB. J Am Chem Soc. 2024 May 30; 2024 May 30. PMID: 38815248.
- Prognostic impact of 'multi-hit' versus 'single hit' TP53 alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases.Badar T, Nanaa A, Atallah E, Shallis RM, Craver EC, Li Z, Goldberg AD, Saliba AN, Patel A, Bewersdorf JP, Duvall A, Burkart M, Bradshaw D, Abaza Y, Stahl M, Palmisiano N, Murthy GSG, Zeidan AM, Kota V, Patnaik MM, Litzow MR. Haematologica. 2024 May 30; 2024 May 30. PMID: 38813716.
- A Bayesian platform trial design with hybrid control based on multisource exchangeability modelling.Wei W, Blaha O, Esserman D, Zelterman D, Kane M, Liu R, Lin J. Stat Med. 2024 May 30; 2024 Apr 9. PMID: 38594809.
- Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trials.Montesinos P, Fathi AT, de Botton S, Stein EM, Zeidan AM, Zhu Y, Prebet T, Vigil CE, Bluemmert I, Yu X, DiNardo CD. Blood Adv. 2024 May 28. PMID: 38507688.
- Scaffold-Oriented Asymmetric Catalysis: Conformational Modulation of Transition State Multivalency during a Catalyst-Controlled Assembly of a Pharmaceutically Relevant Atropisomer.Tampellini N, Mercado BQ, Miller SJ. Chemistry. 2024 May 28; 2024 Apr 11. PMID: 38507249.
- ZFYVE21 promotes endothelial nitric oxide signaling and vascular barrier function in the kidney during aging.Jiang Q, Song G, He L, Li X, Jiang B, Wang Q, Wang S, Kim C, Barkestani MN, Lopez R, Fan M, Wanniarachchi K, Quaranta M, Tian X, Mani A, Gonzalez A, Goodwin JE, Sessa WC, Ishibe S, Jane-Wit D. Kidney Int. 2024 May 24; 2024 May 24. PMID: 38797325.
- Author Correction: Epidemiology, treatment and outcomes of primary renal sarcomas in adult patients.Uhlig J, Uhlig A, Deshpande H, Ströbel P, Trojan L, Lotz J, Hurwitz M, Hafez O, Humphrey P, Grünwald V, Kim HS. Sci Rep. 2024 May 24; 2024 May 24. PMID: 38789511.
- Combining anti-VEGFR and anti-EGFR antibodies: Randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer:(ECOG-ACRIN E7208).Hochster HS, Catalano P, Weitz M, Mitchell EP, Cohen D, O'Dwyer PJ, Faller BA, Kortmanky JS, O'Hara MH, Kricher SM, Lacy J, Lenz HJ, Verma U, Benson AB. J Natl Cancer Inst. 2024 May 22; 2024 May 22. PMID: 38775718.
- Toward a more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS).Efficace F, Buckstein R, Abel GA, Giesinger JM, Fenaux P, Bewersdorf JP, Brunner AM, Bejar R, Borate U, DeZern AE, Greenberg P, Roboz GJ, Savona MR, Sparano F, Boultwood J, Komrokji R, Sallman DA, Xie Z, Sanz G, Carraway HE, Taylor J, Nimer SD, Della Porta MG, Santini V, Stahl M, Platzbecker U, Sekeres MA, Zeidan AM. Hemasphere. 2024 May; 2024 May 21. PMID: 38774655.
- Entering the golden age for antibody-drug conjugates in gynecologic cancer.Greenman M, McNamara B, Mutlu L, Santin AD. Oncoscience. 2024; 2024 May 20. PMID: 38770444.
- Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update.Gordan JD, Kennedy EB, Abou-Alfa GK, Beal E, Finn RS, Gade TP, Goff L, Gupta S, Guy J, Hoang HT, Iyer R, Jaiyesimi I, Jhawer M, Karippot A, Kaseb AO, Kelley RK, Kortmansky J, Leaf A, Remak WM, Sohal DPS, Taddei TH, Wilson Woods A, Yarchoan M, Rose MG. J Clin Oncol. 2024 May 20; 2024 Mar 19. PMID: 38502889.
- Enhancing in vivo cell and tissue targeting by modulation of polymer nanoparticles and macrophage decoys.Piotrowski-Daspit AS, Bracaglia LG, Eaton DA, Richfield O, Binns TC, Albert C, Gould J, Mortlock RD, Egan ME, Pober JS, Saltzman WM. Nat Commun. 2024 May 18; 2024 May 18. PMID: 38762483.
- Hepatotoxicity assessment of innovative nutritional supplements based on olive-oil formulations enriched with natural antioxidants.Prodromou SI, Chatzopoulou F, Saiti A, Giannopoulos-Dimitriou A, Koudoura LA, Pantazaki AA, Chatzidimitriou D, Vasiliou V, Vizirianakis IS. Front Nutr. 2024; 2024 May 15. PMID: 38812942.
- Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-A multicenter cohort study.Bewersdorf JP, Shimony S, Shallis RM, Liu Y, Berton G, Schaefer EJ, Zeidan AM, Goldberg A, Stein E, Marcucci G, Bystrom RP, Lindsley RC, Chen EC, Ramos J, Stein A, Pullarkat V, Aldoss I, DeAngelo DJ, Neuberg DS, Stone RM, Garciaz S, Ball B, Stahl M. Am J Hematol. 2024 May 15; 2024 May 15. PMID: 38751104.
- CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials.Segal NH, Melero I, Moreno V, Steeghs N, Marabelle A, Rohrberg K, Rodriguez-Ruiz ME, Eder JP, Eng C, Manji GA, Waterkamp D, Leutgeb B, Bouseida S, Flinn N, Das Thakur M, Elze MC, Koeppen H, Jamois C, Martin-Facklam M, Lieu CH, Calvo E, Paz-Ares L, Tabernero J, Argilés G. Nat Commun. 2024 May 15; 2024 May 15. PMID: 38750034.
- Modifying the Backbone Chemistry of PEG-Based Bottlebrush Block Copolymers for the Formation of Long-Circulating Nanoparticles.Grundler J, Whang CH, Shin K, Savan NA, Zhong M, Saltzman WM. Adv Healthc Mater. 2024 May 11; 2024 May 11. PMID: 38734871.
- Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes.Tentori CA, Gregorio C, Robin M, Gagelmann N, Gurnari C, Ball S, Caballero Berrocal JC, Lanino L, D'Amico S, Spreafico M, Maggioni G, Travaglino E, Sauta E, Meggendorfer M, Zhao LP, Campagna A, Savevski V, Santoro A, Al Ali N, Sallman D, Sole F, Garcia-Manero G, Germing U, Kroger N, Kordasti S, Santini V, Sanz G, Kern W, Platzbecker U, Diez-Campelo M, Maciejewski JP, Ades L, Fenaux P, Haferlach T, Zeidan AM, Castellani G, Komrokji R, Ieva F, Della Porta MG. J Clin Oncol. 2024 May 9; 2024 May 9. PMID: 38723212.
- Approach to immunotherapy for HCC in the liver transplant population.Block PD, Strazzabosco M, Jaffe A. Clin Liver Dis (Hoboken). 2024 Jan-Jun; 2024 May 3. PMID: 38707244.
- Preclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas.Demirkiran C, Greenman M, Bellone S, McNamara B, Hartwich TMP, Manavella D, Mutlu L, Zipponi M, Yang-Hartwich Y, Yang K, Ratner E, Schwartz PE, Coma S, Pachter J, Santin AD. Gynecol Oncol. 2024 May 3; 2024 May 3. PMID: 38703673.
- The effect of a fermented soy beverage among patients with localized prostate cancer prior to radical prostatectomy.Lokeshwar SD, Ali A, Weiss TR, Reynolds J, Shuch BM, Ferencz T, Kyriakides TC, Mehal WZ, Brito J, Renzulli J, Leapman MS. BMC Urol. 2024 May 3; 2024 May 3. PMID: 38702664.
- Meningioma: International Consortium on Meningiomas (ICOM) consensus review on scientific advances & treatment paradigms for clinicians, researchers, and patients.Wang JZ, Landry AP, Raleigh DR, Sahm F, Walsh KM, Goldbrunner R, Yefet LS, Tonn JC, Gui C, Ostrom QT, Barnholtz-Sloan J, Perry A, Ellenbogen Y, Hanemann CO, Jungwirth G, Jenkinson MD, Tabatabai G, Mathiesen TI, McDermott MW, Tatagiba M, la Fougère C, Maas SLN, Galldiks N, Albert NL, Brastianos PK, Ehret F, Minniti G, Lamszus K, Ricklefs FL, Schittenhelm J, Drummond KJ, Dunn IF, Pathmanaban ON, Cohen-Gadol A, Sulman EP, Tabouret E, Le Rhun E, Mawrin C, Moliterno J, Weller M, Bi WL, Gao A, Yip S, Niyazi M, Aldape K, Wen PY, Short S, Preusser M, Nassiri F, Zadeh G. Neuro Oncol. 2024 May 2; 2024 May 2. PMID: 38695575.
- Epidemiology, treatment and outcomes of primary renal sarcomas in adult patients.Uhlig J, Uhlig A, Deshpande H, Ströbel P, Trojan L, Lotz J, Hurwitz M, Hafez O, Humphrey P, Grünwald V, Kim HS. Sci Rep. 2024 May 2; 2024 May 2. PMID: 38693188.
- Response letter by Nassar et al.Nassar AH, Kim SY, Adib E, Naqash AR, Goldberg SB. J Thorac Oncol. 2024 May. PMID: 38719428.
- Exploiting Metabolic Defects in Glioma with Nanoparticle Encapsulated NAMPT Inhibitors.Murray MA, Noronha KJ, Wang Y, Friedman AP, Paradkar S, Suh HW, Sundaram RK, Brenner C, Saltzman WM, Bindra RS. Mol Cancer Ther. 2024 May 1; 2024 May 1. PMID: 38691846.
- Long-term exposure to ambient fine particulate matter and risk of liver cancer in the NIH-AARP Diet and Health Study.Ma X, Fisher JA, McGlynn KA, Liao LM, Vasiliou V, Sun N, Kaufman JD, Silverman DT, Jones RR. Environ Int. 2024 May; 2024 Apr 5. PMID: 38636274.
- Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147).Sheth SS, Oh JE, Bellone S, Siegel ER, Greenman M, Mutlu L, McNamara B, Pathy S, Clark M, Azodi M, Altwerger G, Andikyan V, Huang G, Ratner E, Kim DJ, Iwasaki A, Levi AW, Buza N, Hui P, Flaherty S, Schwartz PE, Santin AD. Clin Cancer Res. 2024 May 1. PMID: 38592381.
- Essential data variables for a minimum dataset for head and neck cancer trials and clinical research: HNCIG consensus recommendations and database.Baliga S, Abou-Foul AK, Parente P, Szturz P, Thariat J, Shreenivas A, Nankivell P, Bertolini F, Biau J, Blakaj D, Brennan S, Brunet A, De Oliveira TB, Burtness B, Maseda AC, Chow VL, Chua ML, de Ridder M, Garikipati S, Hanai N, Ho FCH, Huang SH, Kiyota N, Klinghammer K, Kowalski LP, Kwong DL, McDowell LJ, Merlano MC, Nair S, Economopoulou P, Overgaard J, Psyrri A, Tribius S, Waldron J, Yom SS, Mehanna H. Eur J Cancer. 2024 May; 2024 Mar 30. PMID: 38579517.
- NCS-1 protein regulates TRPA1 channel through the PI3K pathway in breast cancer and neuronal cells.Sánchez JC, Alemán A, Henao JF, Olaya JC, Ehrlich BE. J Physiol Biochem. 2024 May; 2024 Apr 2. PMID: 38564162.
- Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.Machiels JP, Tao Y, Licitra L, Burtness B, Tahara M, Rischin D, Alves G, Lima IPF, Hughes BGM, Pointreau Y, Aksoy S, Laban S, Greil R, Burian M, Hetnał M, Delord JP, Mesía R, Taberna M, Waldron JN, Simon C, Grégoire V, Harrington KJ, Swaby RF, Zhang Y, Gumuscu B, Bidadi B, Siu LL. Lancet Oncol. 2024 May; 2024 Mar 29. PMID: 38561010.
- An algorithm for standardization of tumor Infiltrating lymphocyte evaluation in head and neck cancers.Xirou V, Moutafi M, Bai Y, Nwe Aung T, Burela S, Liu M, Kimple RJ, Shabbir Ahmed F, Schultz B, Flieder D, Connolly DC, Psyrri A, Burtness B, Rimm DL. Oral Oncol. 2024 May; 2024 Mar 27. PMID: 38547779.
- Clinical physiology: the crucial role of MRI in evaluation of peripheral artery disease.Elsaid NMH, Peters DC, Galiana G, Sinusas AJ. Am J Physiol Heart Circ Physiol. 2024 May 1; 2024 Mar 22. PMID: 38517227.
- Impact of (18)F-FDG PET Intensity Normalization on Radiomic Features of Oropharyngeal Squamous Cell Carcinomas and Machine Learning-Generated Biomarkers.Haider SP, Zeevi T, Sharaf K, Gross M, Mahajan A, Kann BH, Judson BL, Prasad ML, Burtness B, Aboian M, Canis M, Reichel CA, Baumeister P, Payabvash S. J Nucl Med. 2024 May 1; 2024 May 1. PMID: 38514087.
- Pharmacokinetics (PK) of Tiragolumab in First-in-Human Study in Patients with Mixed Solid Tumors (GO30103).Garralda E, Oh DY, Italiano A, Bedard PL, Delord JP, Calvo E, LoRusso P, Wainberg Z, Cervantes A, Rodriguez-Vida A, Shemesh CS, Sane R, Mendus D, Ding H, Hendricks R, Meng R, Cho BC, Kim TW, Wu B. J Clin Pharmacol. 2024 May; 2024 Jan 17. PMID: 38105505.
- Clinical predictive value of renalase in post-ERCP pancreatitis.Muniraj T, Desir G, Gorelick FS, Guo X, Ciarleglio MM, Deng Y, Jamidar PA, Farrell J, Aslanian HR, Laine L. Gastrointest Endosc. 2024 May; 2023 Dec 14. PMID: 38103747.
- Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update Clinical Insights.Rose MG, Kennedy EB, Abou-Alfa GK, Finn RS, Gade T, Kelley RK, Taddei T, Gordan JD. JCO Oncol Pract. 2024 Apr 25; 2024 Apr 25. PMID: 38662970.
- Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice.Chojecki A, Boselli D, Dortilus A, Hamadeh I, Begley S, Chen T, Bose R, Podoltsev N, Zeidan AM, Balmaceda NB, Yacoub A, Ai J, Knight TG, Ragon BK, Shah NA, Sanikommu SR, Symanowski J, Mesa R, Grunwald MR. Ann Hematol. 2024 Apr 25; 2024 Apr 25. PMID: 38662203.
- Challenges in management of older patients with chronic myeloid leukemia.Stempel JM, Shallis RM, Wong R, Podoltsev NA. Leuk Lymphoma. 2024 Apr 23; 2024 Apr 23. PMID: 38652861.
- Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix.Bellone S, Jeong K, Halle MK, Krakstad C, McNamara B, Greenman M, Mutlu L, Demirkiran C, Hartwich TMP, Yang-Hartwich Y, Zipponi M, Buza N, Hui P, Raspagliesi F, Lopez S, Paolini B, Milione M, Perrone E, Scambia G, Altwerger G, Ravaggi A, Bignotti E, Huang GS, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz PE, Quick CM, Angioli R, Terranova C, Zaidi S, Nandi S, Alexandrov LB, Siegel ER, Choi J, Schlessinger J, Santin AD. Proc Natl Acad Sci U S A. 2024 Apr 23; 2024 Apr 16. PMID: 38625939.
- Proof-of-concept studies with a computationally designed M(pro) inhibitor as a synergistic combination regimen alternative to Paxlovid.Papini C, Ullah I, Ranjan AP, Zhang S, Wu Q, Spasov KA, Zhang C, Mothes W, Crawford JM, Lindenbach BD, Uchil PD, Kumar P, Jorgensen WL, Anderson KS. Proc Natl Acad Sci U S A. 2024 Apr 23; 2024 Apr 15. PMID: 38621119.
- Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3-mutant acute myeloid leukemia.Bewersdorf JP, Patel KK, Shallis RM, Podoltsev NA, Kewan T, Stempel J, Mendez L, Stahl M, Stein EM, Huntington SF, Goshua G, Zeidan AM. Leuk Lymphoma. 2024 Apr 22; 2024 Apr 22. PMID: 38648559.
- Vascular mimicry as a facilitator of melanoma brain metastasis.Provance OK, Oria VO, Tran TT, Caulfield JI, Zito CR, Aguirre-Ducler A, Schalper KA, Kluger HM, Jilaveanu LB. Cell Mol Life Sci. 2024 Apr 18; 2024 Apr 18. PMID: 38635031.
- ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts.Hu B, Wiesehöfer M, de Miguel FJ, Liu Z, Chan LH, Choi J, Melnick MA, Arnal Estape A, Walther Z, Zhao D, Lopez-Giraldez F, Wurtz A, Cai G, Fan R, Gettinger S, Xiao A, Yan Q, Homer R, Nguyen DX, Politi K. Cancer Res. 2024 Apr 15. PMID: 38359163.
- Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial.Parra ER, Zhang J, Duose DY, Gonzalez-Kozlova E, Redman MW, Chen H, Manyam GC, Kumar G, Zhang J, Song X, Lazcano R, Marques-Piubelli ML, Laberiano-Fernandez C, Rojas F, Zhang B, Taing L, Jhaveri A, Geisberg J, Altreuter J, Michor F, Provencher J, Yu J, Cerami E, Moravec R, Kannan K, Luthra R, Alatrash G, Huang HH, Xie H, Patel M, Nie K, Harris J, Argueta K, Lindsay J, Biswas R, Van Nostrand S, Kim-Schulze S, Gray JE, Herbst RS, Wistuba II, Gettinger S, Kelly K, Bazhenova L, Gnjatic S, Lee JJ, Zhang J, Haymaker C. Clin Cancer Res. 2024 Apr 15. PMID: 38277235.
- Identifying Opportunities to Deliver High-Quality Cancer Care Across a Health System: A Clinical Responsibility.Shah HP, Cohen O, Bourdillon AT, Burtness BA, Boffa DJ, Young M, Judson BL, Mehra S. Otolaryngol Head Neck Surg. 2024 Apr 12; 2024 Apr 12. PMID: 38606669.
- pHLIP targeted intracellular delivery of calicheamicin.DuPont M, Klumpp C, Iraca M, Allababidi D, Visca H, Engelman DM, Andreev OA, Moshnikova A, Reshetnyak YK. Int J Pharm. 2024 Apr 10; 2024 Feb 28. PMID: 38428548.
- Clinical Predictors of Survival in Patients With BRAFV600-Mutated Metastatic Melanoma Treated With Combined BRAF and MEK Inhibitors After Immune Checkpoint Inhibitors.Kahn AM, Perry CJ, Etts K, Kluger H, Sznol M. Oncologist. 2024 Apr 4. PMID: 37971411.
- Lifileucel, an Autologous Tumor-infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors.Schoenfeld AJ, Lee SM, Doger de Speville B, Gettinger SN, Hafliger S, Sukari A, Papa S, Rodriguez-Moreno JF, Graf Finckenstein F, Fiaz R, Catlett M, Chen G, Qi R, Masteller EL, Gontcharova V, He K. Cancer Discov. 2024 Apr 2; 2024 Apr 2. PMID: 38563600.
- Development of a Small Molecule Downmodulator for the Transcription Factor Brachyury.Chase DH, Bebenek AM, Nie P, Jaime-Figueroa S, Butrin A, Castro DA, Hines J, Linhares BM, Crews CM. Angew Chem Int Ed Engl. 2024 Apr 2; 2024 Feb 28. PMID: 38348945.
- Differential Effect of Consolidative Thoracic Radiation Therapy in Extensive-Stage Small Cell Lung Cancer Based on Sex.Jairam V, Soulos PR, K C M, Gross CP, Slotman BJ, Chiang AC, Park HS. Adv Radiat Oncol. 2024 Apr; 2023 Dec 3. PMID: 38778819.
- Melanocortin-1 Receptor Expression as a Marker of Progression in Melanoma.Su DG, Djureinovic D, Schoenfeld D, Marquez-Nostra B, Olino K, Jilaveanu L, Kluger H. JCO Precis Oncol. 2024 Apr. PMID: 38662983.
- The Pancreatic Cancer Early Detection (PRECEDE) Study is a Global Effort to Drive Early Detection: Baseline Imaging Findings in High-Risk Individuals.Zogopoulos G, Haimi I, Sanoba SA, Everett JN, Wang Y, Katona BW, Farrell JJ, Grossberg AJ, Paiella S, Klute KA, Bi Y, Wallace MB, Kwon RS, Stoffel EM, Wadlow RC, Sussman DA, Merchant NB, Permuth JB, Golan T, Raitses-Gurevich M, Lowy AM, Liau J, Jeter JM, Lindberg JM, Chung DC, Earl J, Brentnall TA, Schrader KA, Kaul V, Huang C, Chandarana H, Smerdon C, Graff JJ, Kastrinos F, Kupfer SS, Lucas AL, Sears RC, Brand RE, Parmigiani G, Simeone DM. J Natl Compr Canc Netw. 2024 Apr. PMID: 38626807.
- Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer.McNamara B, Demirkiran C, Hartwich TMP, Bellone S, Manavella D, Mutlu L, Greenman M, Zipponi M, Yang-Hartwich Y, Yang K, Ratner E, Schwartz PE, Coma S, Pachter JA, Santin AD. Gynecol Oncol. 2024 Apr; 2024 Mar 15. PMID: 38493021.
- VEGF-C prophylaxis favors lymphatic drainage and modulates neuroinflammation in a stroke model.Boisserand LSB, Geraldo LH, Bouchart J, El Kamouh MR, Lee S, Sanganahalli BG, Spajer M, Zhang S, Lee S, Parent M, Xue Y, Skarica M, Yin X, Guegan J, Boyé K, Saceanu Leser F, Jacob L, Poulet M, Li M, Liu X, Velazquez SE, Singhabahu R, Robinson ME, Askenase MH, Osherov A, Sestan N, Zhou J, Alitalo K, Song E, Eichmann A, Sansing LH, Benveniste H, Hyder F, Thomas JL. J Exp Med. 2024 Apr 1; 2024 Mar 5. PMID: 38442272.
- Correction: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.Roque DM, Siegel ER, Buza N, Bellone S, Silasi DA, Huang GS, Andikyan V, Clark M, Azodi M, Schwartz PE, Rao GG, Reader JC, Hui P, Tymon-Rosario JR, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin AD. Br J Cancer. 2024 Apr. PMID: 38438590.
- Compartmentalized ocular lymphatic system mediates eye-brain immunity.Yin X, Zhang S, Lee JH, Dong H, Mourgkos G, Terwilliger G, Kraus A, Geraldo LH, Poulet M, Fischer S, Zhou T, Mohammed FS, Zhou J, Wang Y, Malloy S, Rohner N, Sharma L, Salinas I, Eichmann A, Thomas JL, Saltzman WM, Huttner A, Zeiss C, Ring A, Iwasaki A, Song E. Nature. 2024 Apr; 2024 Feb 28. PMID: 38418880.
- Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML.Shimony S, Bewersdorf JP, Shallis RM, Liu Y, Schaefer EJ, Zeidan AM, Goldberg AD, Stein EM, Marcucci G, Lindsley RC, Chen EC, Ramos Perez J, Stein A, DeAngelo DJ, Neuberg DS, Stone RM, Ball B, Stahl M. Leukemia. 2024 Apr; 2024 Feb 20. PMID: 38378841.